Cabot Corporation
NYSE:CBTChemicals - Specialty
+$0.96 today
- Market cap
- $3.80B
- Beta
- 0.83
- P/E (TTM)
- 16.3
- EPS (TTM)
- $5.48
- Dividend yield
- 2.04%
Volume 0.53M
Average 0.43M
CBT Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Cabot CorporationNYSE: CBT
Capital Expenditures · Q3 FY2026 · quarter ended Jun 2026
Capital expenditures growth accelerates
Q3 FY2026 capital expenditures of $38M (cash outflow) rose 11.8% year over year, ahead of the -28.5% change in trailing-twelve-month capital expenditures. Sequentially, it fell 15.6% from the prior quarter. Over 3 fiscal years it compounded at +9.1% a year.
Context
- Capital expenditures amounted to 7.4% of revenue in FY2025, up 1.3 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +11.8% holds above the trailing-twelve-month pace of -28.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (274M) USD
- Year-over-year change
- -13.7%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (274M) | -13.7% |
| FY2024 | 2024-09-30 | (241M) | +1.2% |
| FY2023 | 2023-09-30 | (244M) | -15.6% |
| FY2022 | 2022-09-30 | (211M) | -8.2% |
| FY2021 | 2021-09-30 | (195M) | — |
Capital Expenditures vs competitors
How CBT compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -28.5% is the 8th highest of 11, against a peer median of -3.0%.
- Capital expenditures amounts to 5.9% of revenue for CBT, versus a peer median of 4.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2026 | ZAR 20.55B ZAR | -19.1% | -12.6% | 7.7% | |
| LTM Jun 2026 | $276M USD | -28.9% | -14.2% | 2.8% | |
| LTM Jun 2026 | $269.62M USD | -9.3% | +25.0% | 8.2% | |
| LTM Jun 2026 | $216M USD | -28.5% | +9.1% | 5.9% | |
| LTM Aug 2026 | $189.33M USD | +56.4% | +3.1% | 5.3% | |
| LTM Jun 2026 | $118.89M USD | +59.8% | +4.1% | 7.0% | |
| LTM Sep 2026 | $108.8M USD | +3.3% | +0.3% | 3.2% | |
| LTM Jun 2026 | $57.99M USD | -63.8% | -44.1% | 1.4% | |
| LTM Sep 2026 | $56.25M USD | +27.4% | +6.4% | 4.9% | |
| LTM Jun 2026 | $30.73M USD | -28.8% | +50.9% | 4.1% | |
| LTM Aug 2026 | $7.4M USD | +63.5% | +2.5% | 1.1% | |
| Peer median (excluding CBT) | — | -3.0% | +2.8% | 4.5% | |
Competitors are the stored peer set for CBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | 286M | 243M | 484M | 424M | 376M |
| Depreciation & Amortization | 160M | 146M | 144M | 151M | 154M |
| Deferred Income Tax | 9M | (40M) | (156M) | (37M) | 32M |
| Stock-Based Compensation | 21M | 23M | 20M | 25M | 24M |
| Change in Working Capital | (244M) | (448M) | 100M | 70M | 49M |
| Accounts Receivables | 7M | (287M) | 153M | (26M) | 76M |
| Inventory | (174M) | (259M) | 96M | 41M | 47M |
| Accounts Payables | 167M | 115M | (152M) | 42M | (67M) |
| Other Working Capital | (244M) | (17M) | 3M | 13M | (7M) |
| Other Non-Cash Items | 25M | 176M | 3M | 59M | 30M |
| Operating Cash Flow | 257M | 100M | 595M | 692M | 665M |
| Capital Expenditures | (195M) | (211M) | (244M) | (241M) | (274M) |
| Acquisitions (Net) | (92M) | 70M | 6M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 101M | 23M | 24M | 6M | (24M) |
| Investing Cash Flow | (186M) | (118M) | (214M) | (235M) | (298M) |
| Debt Repayment | 36M | 298M | (179M) | (143M) | (23M) |
| Common Stock Issued | 6M | 6M | 4M | 20M | 8M |
| Common Stock Repurchased | (3M) | (53M) | (98M) | (172M) | (168M) |
| Dividends Paid | (80M) | (84M) | (88M) | (93M) | (96M) |
| Other Financing Activities | (19M) | (22M) | (42M) | (27M) | (57M) |
| Financing Cash Flow | (60M) | 145M | (403M) | (415M) | (336M) |
| Effect of Forex Changes | 8M | (91M) | 54M | (57M) | 4M |
| Net Change in Cash | 19M | 36M | 32M | (15M) | 35M |
| Free Cash Flow | 62M | (111M) | 351M | 451M | 391M |
Cabot Corporation
NYSE:CBT
Intrinsic Alpha fair value
Locked
Current Price
$74.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.